Autoantibodies could shape cancer risk, growth and response to immunotherapy
Researchers are investigating the role of autoantibodies in cancer risk, growth, and immunotherapy response. The study, led by the ATLAS team, aims to determine if these immune proteins can be used to predict or treat cancer.
Why it matters
Understanding the immune system's interaction with cancer could lead to breakthroughs in personalized medicine and more effective cancer prevention strategies.
edited by Lisa Lock , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Pixabay/CC0 Public Domain Scientists have long sought to understand why some people with no known risk factors develop cancer while others with significant risk never do. The answer may lie in immune proteins known as autoantibodies (auto-Abs), suggests a commentary published in Cell co-authored by a team that includes Jean-Laurent Casanova, M.D., Ph.D., a professor in the Center for the Genetics of Host Defense and Children's Medical Center Research Institute at UT Southwestern (CRI).
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in